Урсохол may be relevant in contexts marked by increased discomfort or tension. The medicine is commonly used across conditions presenting with acute episodes or those where functional stability becomes affected.

The primary therapeutic domain for Урсохол involves symptomatic support for conditions presenting with systemic or localized discomfort, and is considered relevant for easing symptoms associated with heightened systemic burden. This application is often used in clinical scenarios where short-term symptomatic assistance is needed.

Support for Symptomatic Discomfort in Biliary Tract Issues

This therapeutic domain helps address symptom clusters that may become intense or disruptive in situations involving certain distressing symptoms. It is used in areas where short-term symptom management is appropriate, providing support that helps ease the overall symptom burden.

Support for Chronic Conditions Marked by Systemic Discomfort

Урсохол is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes. It contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Quick Fact: Support in Managing Disruptive Symptoms

The medication offers symptomatic relief that helps patients cope more steadily with symptoms that interfere with daily functioning.

Regulatory References

1. Ursodeoxycholic Acid 150 mg tablets information from the electronic Medicines Compendium

Who Can and Cannot Use Урсохол?

The official regulatory documentation for Ursodeoxycholic Acid defines population eligibility primarily through a list of absolute prohibitions related to the biliary system and specific comorbidities.

Populations for Whom Use is Contraindicated

Use of Урсохол is strictly prohibited (contraindicated) for patients with:

• Acute inflammation of the gallbladder or biliary tract.
• Biliary tract occlusion (e.g., of the common bile duct or cystic duct).
• Non-functioning gallbladder or impaired gallbladder contractility.
• Radio-opaque calcified gallstones or stones requiring surgery.
• Severe liver disease, decompensated hepatic cirrhosis, or frequent episodes of biliary colic.
• Active gastric and duodenal ulcers or inflammatory diseases of the small and large intestine.
• Hypersensitivity to bile acids or any component of the formulation.

Restricted and Conditional Use

• Pregnancy and Lactation: The medicine must not be used during pregnancy unless clearly necessary. Women of childbearing potential must use reliable contraception during treatment. Use is not recommended during breastfeeding.
• Pediatric Use: Safety and efficacy are not established for general use in children. Use is restricted to those aged 6 years to less than 18 years for specific hepatobiliary disorders associated with cystic fibrosis, as documented in European labeling.

Interactions with other medicines and products

Official regulatory documents describe several important interactions for Ursodeoxycholic Acid, the active ingredient in Урсохол. These interactions involve changes in drug absorption (pharmacokinetics) or interference with the intended therapeutic effect (pharmacodynamics).

Interactions Affecting Урсохол Efficacy

• Bile Acid Sequestrants and Antacids: Medicines such as cholestyramine, colestipol, and aluminum hydroxide-containing antacids bind bile acids in the intestine. This action reduces the absorption and effectiveness of Урсохол. To manage this interaction, these agents must be administered at least two hours before or two hours after taking Урсохол.
• Hormones and Lipid-Lowering Agents: Oestrogens, oral contraceptives, and cholesterol-lowering agents like clofibrate can increase cholesterol secretion into the bile, which counteracts the intended effect of Урсохол to dissolve cholesterol gallstones. Simultaneous use is generally restricted, especially in patients undergoing gallstone dissolution treatment.

Interactions Affecting Co-administered Medicines

• Altered Absorption of Specific Drugs: Урсохол may reduce the intestinal absorption and, consequently, the efficacy of certain antibiotics (like ciprofloxacin and dapsone) and calcium channel blockers (such as nitrendipine). Conversely, it has been documented to increase the absorption of Cyclosporine, a drug used to suppress the immune system. This necessitates close monitoring of the co-administered drug’s blood levels and potential dosage adjustments by a healthcare provider.

Урсохол (ursodeoxycholic acid or UDCA) is a naturally occurring hydrophilic bile acid that, upon systemic exposure, becomes a major fraction of the endogenous bile acid pool. Its primary mechanism involves the competitive displacement of more hydrophobic, potentially cytotoxic bile acids, thereby altering the overall hydrophobicity index of the secreted bile.

At the cellular level, UDCA accumulates within hepatocytes and cholangiocytes. It functions as a cytoprotective agent, stabilizing both the cell plasma membranes and the inner mitochondrial membrane, thus inhibiting the mitochondrial-mediated pathway of apoptosis. This anti-apoptotic effect involves the prevention of cytochrome C release and subsequent caspase activation. Furthermore, UDCA modulates hepatobiliary secretion, exhibiting a choleretic effect. This involves increasing the concentration of intracellular calcium, which stimulates the activity and insertion of key transport proteins, such as the Cl^-- HCO3^- anion exchanger (AE2), into the canalicular membrane, promoting vesicular exocytosis and resultant bile flow. Systemically, UDCA reduces the intestinal absorption of cholesterol and decreases hepatic cholesterol synthesis, leading to a reduction in the cholesterol saturation of bile.

Official Administration Guidelines for Урсохол

The administration of Урсохол (Ursodeoxycholic Acid, UDCA) is based on established parameters. The approved route for this medicine is oral ingestion (taken by mouth).

Dosing and Frequency

The required dose is determined on a milligram-per-kilogram (mg/kg) body weight basis, which varies depending on the intended use pattern. For instance, the standard regimen for certain chronic liver conditions is typically 13 to 15 mg/kg per day, while for gallstone dissolution, the dose is generally 8 to 10 mg/kg per day.

The total daily dosage must be administered in two to four divided doses to maintain therapeutic levels. Administration of the medicine is required with food (at meals) to ensure optimal absorption.

Procedural Use and Duration

• Preparation: Capsules and tablets must be swallowed whole with water and must not be chewed or crushed. Some scored tablets are designed to be split solely for precise dose adjustment, as specified in the labeling.
• Duration: Therapy for gallstone dissolution requires months to two years of continuous use, and must be maintained for three months after radiological confirmation of stone disappearance. Treatment for certain chronic liver conditions is typically long-term.
• Monitoring Mandate: Continuous use is conditioned on a procedural requirement for liver function tests (including gamma-GT, AST, and ALT) to be conducted monthly for the first three months of therapy, and then every six months thereafter.

These requirements establish the standardized protocol for the administration and continuation of Ursodeoxycholic Acid.

Research Evidence / Overview of Studies for Урсохол

Evidence for Use in Dissolution of Cholesterol Gallstones

Ursodeoxycholic Acid (Урсохол) was evaluated in research exploring the dissolution of certain types of gallstones. Research primarily involved Randomized Controlled Trials (RCTs) and studies that evaluated changes in the size and composition of small, non-calcified gallstones in patients with a functioning gallbladder. Studies described patterns observed where a measurable change in stone size was observed in a subset of the studied population over follow-up periods, which often spanned 6 to 24 months. However, data show patterns related to high rates of stone recurrence after the cessation of administration. The evidence provides limited information regarding patients with large or calcified stones, as these populations were generally excluded from key trials.

Evidence for Use in Primary Biliary Cholangitis (PBC)

For the chronic liver condition Primary Biliary Cholangitis (PBC), the evidence base relies on RCTs, systematic reviews, and large-scale, long-term observational cohort studies. Research examined the administration of UDCA in adult patients with PBC to monitor changes related to the course of the disease over many years. Studies explored endpoints including all-cause mortality, the need for a liver transplant, and changes in liver biochemistry markers (e.g., Alkaline Phosphatase and bilirubin).

Long-term data describe patterns related to the rate of clinical events such as liver transplantation when comparing observed UDCA groups to control groups. Studies reported changes measured during the study period in liver enzyme levels, including shifts toward normalized ranges in patients who met the criteria for biochemical response. However, findings were mixed when trials assessed patient-reported outcomes describing perceived discomfort, such as chronic fatigue or pruritus, and the evidence for consistent symptom management remains limited.

Understanding the Study Limitations and Research Gaps

Overall, the research for UDCA presents distinct limitations. Evidence quality varies across studies, and the ability to generalize findings is restricted by the narrow selection criteria used in many gallstone trials. Certainty remains low regarding the impact of UDCA on common patient-reported outcomes. Furthermore, comparative evidence is lacking for managing the subset of patients who do not demonstrate an early biochemical response.

Key Studies & References

1. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (AASLD)

Common questions about Урсохол (FAQ)

Q: Can children 2 years old use it?

A: According to official product information for over-the-counter (OTC) acetaminophen, these products are generally not recommended for children under 2 years of age unless a doctor specifically advises it. For children aged 2 years and older, dosage must be carefully calculated based on the child's weight or age, and it is important to adhere closely to the instructions provided on the product label.

Q: Is it safe long-term?

A: Regulatory documents indicate that acetaminophen products are intended for short-term use for relieving pain and fever. Labels commonly advise consulting a healthcare professional if pain lasts longer than 10 days (5 days for children) or if fever persists beyond 3 days. If there is a need for use over an extended period, it is important to seek advice from a healthcare professional.

Q: Can I use this while pregnant?

A: Official information states that if it is medically necessary, acetaminophen can be used during pregnancy. The recommendation is to use the lowest effective dose for the shortest duration possible to reduce the pain or fever. If the medicine is needed more frequently or does not help with symptoms, consulting a healthcare professional is recommended.

How to Store and Dispose of Ursodeoxycholic Acid

The storage and disposal of Ursodeoxycholic Acid must strictly follow regulatory guidelines to maintain product integrity and ensure safety.

Official Storage Requirements

Disposal of Product

Unused or expired Ursodeoxycholic Acid must be disposed of according to local pharmaceutical waste regulations. The medicine must not be thrown into household waste or flushed down wastewater to prevent environmental contamination.